Although under pressure today, the All Ordinaries Index (ASX: XAO) is up 1.3% so far in 2025, with three ASX All Ords shares racing ahead of those gains.
At market close yesterday, these three companies were leading the charge higher in the nascent new year.
You'll also notice a decided trend in the sector they operate in.
Which soaring ASX All Ords shares are we talking about?
Read on!
ASX All Ords shares setting the bar high for 2025
The third-best performing stock on our list (bumped from second place at Thursday's close) is Imugene Ltd (ASX: IMU).
Shares in the ASX All Ords healthcare stock closed out 2024 trading for 3.7 cents. In afternoon trade on Friday, shares are changing hands for 4.3 cents apiece, up 16.2% in 2025.
Imugene attracted significant investor interest after the company released an update on a clinical trial last Friday. Shares leapt 12.8% on Monday.
Imugene reported that the first Australian patient had been dosed in the Phase 1b clinical trial at the Royal Prince Alfred Hospital (RPAH) in Sydney.
As the Motley Fool reported on the day:
This trial is focused on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which is one of the most challenging and aggressive forms of non-Hodgkin's lymphoma.
"Achieving first patient dosed for azer-cel in Australia represents a significant milestone for Imugene and for Australian patients battling this devastating disease," Imugene CEO Leslie Chong said.
This brings us to the second-best-performing ASX All Ords share of 2025 (moving up from number three at Thursday's close): Cyclopharm Ltd (ASX: CYC).
Shares in the healthcare stock closed on 31 December trading for $1.585. At the time of writing today, shares are swapping hands for $1.985 apiece, up 25.2% year to date.
The last price-sensitive news released by Cyclopharm was back on 20 December.
In a response to an ASX price query on the rapid gains posted, the ASX All Ords company said it was not "aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities".
Cyclopharm added that it was "carrying on business in the ordinary course in accordance with its disclosed strategic direction and commercialisation plan".
At the head of the pack in 2025
At the head of the pack in these early days of 2025 is Silicon Valley-based EBR Systems Inc (ASX: EBR), which is focused on treating cardiac rhythm disease. (Did you pick up the sector trend yet?)
The EBR Systems share price closed out 2024 at $1.025. In Friday afternoon trade, shares are changing hands for $1.40 apiece. That sees this ASX All Ords stock up 36.6% already in the new year.
On Monday, the company, which is developing the world's only wireless cardiac pacing device for heart failure (WiSE), reported that the US Food and Drug Administration (FDA) had scheduled the manufacturing Pre-Approval Inspection (PAI) to commence on 14 January.
"This significant milestone brings us even closer to US commercialisation and to making available our life-changing WiSE technology to heart failure patients in need," EBR Systems CEO John McCutcheon said.
